This is hereby announced
Guangzhou Baiyunshan Hanfang Modern Pharmaceutical Co., Ltd. has successfully completed the work related to shareholding system reform and was officially renamed Guangzhou Baiyunshan Hanfang Modern Pharmaceutical Co., Ltd. on March 27, 2026. This renaming marks a solid step forward for the company on the path of market-oriented reform and standardized governance, ushering in a new journey of high-quality development.
About Us
Baiyunshan Hanfang is a high-tech enterprise wholly owned by Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd. (Guangzhou Pharmaceutical Group), an A+H share listed company under Guangzhou Pharmaceutical Group. The company focuses on the biopharmaceutical and health industries, specializing in the research, development, production, and sales of specialty APIs, fat emulsion excipients, health foods, and special medical foods.
As a “science and technology reform enterprise” recognized by the State-owned Assets Supervision and Administration Commission of the State Council and a “Little Giant” enterprise specializing in niche fields designated by the Ministry of Industry and Information Technology, the company relies on the “National Engineering Research Center for Traditional Chinese Medicine Pharmaceutical Process Technology and New Drug Creation.” It maintains a leading position in the specialty API sub-sector, has built the largest domestic production base for pharmaceutical lipid excipients with internationally advanced technology, and continuously promotes the high-quality development of the pharmaceutical and health industry.
The road of reform moves forward with firm steps
As an active practitioner of state-owned enterprise reform, Baiyunshan Hanfang has always closely followed the requirements of the action plan for deepening and upgrading state-owned enterprise reform, steadily advancing various reform initiatives:
In November 2025, the company successfully completed mixed-ownership reform, introducing five strategic investors and implementing equity incentives for key technical personnel and management staff, thereby establishing a diversified equity structure and achieving a crucial breakthrough in the market-oriented reform of state-owned enterprises. Since then, with the core objectives of clarifying property rights and establishing a modern corporate governance system, the company has continued to deepen shareholding system reform, constantly improving a governance system characterized by clear rights and responsibilities and efficient operation, laying a solid foundation for the company’s long-term development.
Embarking on a New Journey, Fulfilling New Promises
The new name carries a new mission, and the new starting point ushers in a new journey. After the renaming, Guangzhou Baiyunshan Hanfang Modern Pharmaceutical Co., Ltd. will always stay true to its original aspiration and bravely shoulder its mission, taking “becoming a trusted health guardian for families worldwide” as its vision and practicing the mission of “focusing on innovation, creating outstanding products, and contributing to high-quality health and longevity for humanity.”
In the future, the company will continue to deeply cultivate the pharmaceutical and health fields, making all-out efforts to open up a new situation of high-quality development, contributing greater strength to Guangzhou Pharmaceutical Group’s journey toward building a “world-class, science-and-technology-driven pharmaceutical and health industry group,” injecting new momentum into the implementation of the “Healthy China” strategy and the prosperous development of the pharmaceutical and health industry, and writing new chapters!
We sincerely thank leaders at all levels, partners, and friends from all sectors of society for their long-term care and support, and look forward to continuing to work hand-in-hand with you to build a healthy future together!
